This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. Serious ...

Cosentyx may soon share the hidradenitis suppurativa (HS) field with another inflammatory biologic—but, for now, the Novartis drug has a head start. That’s good news for the Swiss Pharma, given that ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

The approval was based on data from the phase 3 SUNSHINE and SUNRISE trials, which included 1084 adults with moderate to severe HS. Results showed a significantly greater proportion of patients ...

Atopic dermatitis and psoriasis are well-established battlefields for anti-inflammatory biologic drugs. Now, two drugmakers are preparing to launch products in a lesser-known disease area with ...

Please provide your email address to receive an email when new articles are posted on . Cosentyx is the first human biologic that directly inhibits interleukin-17A to be approved in any disease. The ...

Basel, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA’s approval of Cosentyx was the most read Healio ...

Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...

Novartis (NYSE:NVS) is throwing in the towel on a phase 3 program to gain an additional approval for its blockbuster Cosentyx (secukinumab) for active peripheral spondyloarthritis. The change in plans ...

Novartis has come up short in its bid to expand its blockbuster drug Cosentyx to an autoimmune disease whose only biologic treatment options are an old Roche drug and the biosimilars that have ...

The approval was based on data from two phase 3 trials that evaluated the use of Cosentyx in patients 6 to 18 years of age with severe plaque psoriasis who were candidates for systemic therapy. The ...